Celularity Inc. Increase (Decrease) in Other Operating Assets and Liabilities, Net
Celularity Inc. (CELU) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of -$300.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2026-04-30
- Celularity Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2024-12-31 was -$585.00K.
- Celularity Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2024-09-30 was -$1.00K.
- Celularity Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2024-06-30 was $467.00K.
- Celularity Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2024-03-31 was -$181.00K.
- Celularity Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2024 was -$300.00K.
- Celularity Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2023 was -$4.16M, a 11335.14% decline from fiscal 2022.
- Celularity Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2022 was $37.00K.
- Celularity Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2021 was -$2.63M.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$585.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | -$586.00K derived: sum of 2 quarters · filed 2026-04-30 | -$119.00K derived: sum of 3 quarters · filed 2026-04-30 | -$300.00K 10-K · filed 2026-04-30 |
| 2024-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $466.00K derived: sum of 2 quarters · filed 2025-11-14 | $285.00K 10-Q · filed 2025-11-14 | -$1.86M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $467.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $286.00K 10-Q · filed 2025-08-29 | -$1.86M derived: sum of 3 quarters · filed 2025-08-29 | -$3.00M derived: sum of 4 quarters · filed 2025-08-29 |
| 2024-03-31 | -$181.00K 10-Q · filed 2025-08-29 | -$2.33M derived: sum of 2 quarters · filed 2025-08-29 | -$3.46M derived: sum of 3 quarters · filed 2025-08-29 | -$4.07M derived: sum of 4 quarters · filed 2025-08-29 |
| 2023-12-31 | -$2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | -$3.28M derived: sum of 2 quarters · filed 2025-05-08 | -$3.88M derived: sum of 3 quarters · filed 2025-05-08 | -$4.16M 10-K · filed 2025-05-08 |
| 2023-09-30 | -$1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-06 | -$1.74M derived: sum of 2 quarters · filed 2024-12-06 | -$2.01M 10-Q · filed 2024-12-06 | -$3.41M derived: sum of 4 quarters · filed 2024-12-06 |
| 2023-06-30 | -$604.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | -$876.00K 10-Q · filed 2024-11-07 | -$2.27M derived: sum of 3 quarters · filed 2024-11-07 | -$1.05M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | -$272.00K 10-Q · filed 2024-10-16 | -$1.67M derived: sum of 2 quarters · filed 2024-10-16 | -$447.00K derived: sum of 3 quarters · filed 2024-10-16 | -$139.00K derived: sum of 4 quarters · filed 2024-10-16 |
| 2022-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | -$175.00K derived: sum of 2 quarters · filed 2024-07-30 | $133.00K derived: sum of 3 quarters · filed 2024-07-30 | $37.00K 10-K · filed 2024-07-30 |
| 2022-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-03 | $1.53M derived: sum of 2 quarters · filed 2024-01-03 | $1.43M 10-Q · filed 2024-01-03 | $2.01M derived: sum of 4 quarters · filed 2024-01-03 |
| 2022-06-30 | $308.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $212.00K 10-Q · filed 2023-08-14 | $791.00K derived: sum of 3 quarters · filed 2023-08-14 | $634.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$96.00K 10-Q · filed 2023-05-22 | $483.00K derived: sum of 2 quarters · filed 2023-05-22 | $326.00K derived: sum of 3 quarters · filed 2023-05-22 | -$2.77M derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $579.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $422.00K derived: sum of 2 quarters · filed 2023-03-31 | -$2.67M derived: sum of 3 quarters · filed 2023-03-31 | -$2.63M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$157.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$3.25M derived: sum of 2 quarters · filed 2022-11-10 | -$3.21M 10-Q · filed 2022-11-10 | -$3.32M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$3.05M 10-Q · filed 2022-08-09 | -$3.16M derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | $47.00K 10-Q · filed 2022-05-16 | -$64.00K derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | -$111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$70.00K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $41.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |